Journal of International Oncology ›› 2013, Vol. 40 ›› Issue (2): 149-152.

Previous Articles     Next Articles

Inhibitory effect of antisense miR-30a-5p on glioma cell growth in vivo

SUN  Ji-Kui, JIA  Zhi-Fan, PU  Pei-Yu, WANG  Guang-Xiu, ZHANG  An-Ling, YANG  Wei-Dong   

  1. Laboratory of Neuro-Oncology, Tianjin Neurological Institute, Tianjin Medical University General Hospital, Tianjin 300052, China
  • Online:2013-02-08 Published:2013-01-25
  • Contact: Corresponding author: YANG Wei-dong, E-mail: yangweidongshine@sina.com E-mail:yangweidongshine@sina.com

Abstract: Objective To study the inhibitory effect of knocking down miR-30a-5p on the U87 human glioma xenograft growth and its possible mechanism. Methods Nude mice bearing subcutaneous U87 human glioblastoma were established and treated with miR-30a-5p antisense oligonucleotides (AS-miR-30a-5p) subcutaneous injection. Tumor size was measured every other day until the observation period ended. Researchers executed the animals after the treatment, stripped tumor tissues and extracted RNA and protein. Real-time PCR were conducted to detect the expression of miR-30a-5p. The histopathological characteristics and proliferation and apoptosis biological characters (including SEPT7, PCNA, cyclinD1, MMP-2, apoptosis related factor P53, bcl-2 and caspase3)were evaluated by HE and immunohistochemical staining, Western blot analysis respectively, and the cell apoptosis was detected by TUNEL method. Results In AS-miR-30a-5p treated group, the tumor growth was delayed and the final tumor volume was smaller than that in the control and scr-ODN treated group (F=7.167, P<0.05), and the expression of miR-30a-5p was knocked down. The expression of PCNA、cyclinD1 were significantly down-regulated while P53、SEPT7 and caspase3 up-regulated. Apoptotic index was increased significantly. Conclusion As-miR-30a-5p suppresses the growth of U87 human gliomas xenografts significantly. Malignant phenotype of tumors are reversed to a considerable degree. Therefore, miR-30a-5p can be a candidate for targeted therapy of human glioma.

Key words: Giomas, Oligonucleotides, antisense, Drug therapy, miR-30a-5p